Relative persistence of AAV serotype 1 vector genomes in dystrophic muscle
2008

Persistence of AAV Vector Genomes in Dystrophic Muscle

Sample size: 4 publication Evidence: moderate

Author Information

Author(s): Christina A. Pacak, Thomas J. Conlon, Cathryn S. Mah, Barry J. Byrne

Primary Institution: University of Florida

Hypothesis

The therapeutic vector would establish long-term persistence through prevention of myofiber turnover.

Conclusion

The therapeutic vector maintained vector genome persistence in skeletal muscle better than the reporter vector.

Supporting Evidence

  • The therapeutic vector led to prolonged vector genome persistence in skeletal muscle.
  • Loss of vector genomes was observed in muscles not protected by therapeutic gene transfer.
  • The study suggests that fast-twitch muscle fibers may turnover more rapidly than slow-twitch fibers.

Takeaway

This study shows that a special virus can help muscles stay healthy longer in mice with a muscle disease.

Methodology

Mice were injected with two types of vectors in their hindlimbs, and muscle samples were analyzed for vector genome persistence at 4 and 12 months post-injection.

Potential Biases

Potential bias in the assessment of muscle fiber turnover due to uneven vector distribution.

Limitations

The delivery method may not distribute the vector evenly across all muscle fibers.

Participant Demographics

One-day-old alpha sarcoglycan knockout mice.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1479-0556-6-14

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication